During a live event, Mark Yarchoan, MD, and participants discussed their impressions of the CheckMate-9DW trial data in ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

ASCO 2025 showcases breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Michael Caligiuri, MD, discusses the modulation of natural killer cells to enhance their ability to detect and destroy tumor cells.

FDA fast-tracks DB-1310, a novel HER3-targeting ADC, offering hope for advanced NSCLC patients with unmet treatment needs.

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate cancer.

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits ...

FDA issues a complete response letter for glofitamab's second-line DLBCL indication, highlighting ongoing scrutiny in ...